Friday, July 10, 2026

pharma · Acquired Blepharoptosis · Diabetic Macular Edema

Santen Oy

Santen Oy clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

TAMPERE, FI HQ
15 Employees
EMA registrant Type
Company details
Status
Public
HQ
TAMPERE, FI
Employees
15
Programs
3
Drugs
8
Patents
0
Intelligence · Clinical Programs

Santen Oy projects

2 ClinicalTrials.gov programs sponsored by Santen Oy.

Santen Oy has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 101380003SA

    Santen Oy

    Acquired Blepharoptosis

    phase 3 small molecule active

    1 trial
  2. Betamethasone Microsphere (DE-102) Low Dose

    Santen Oy

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Santen Oy have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.